Eledon Pharmaceuticals (ELDN)
(Delayed Data from NSDQ)
$2.73 USD
-0.01 (-0.36%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $2.66 -0.07 (-2.56%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELDN 2.73 -0.01(-0.36%)
Will ELDN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELDN
Are Medical Stocks Lagging DaVita (DVA) This Year?
Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
ELDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy?
Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade
Eledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for ELDN
Eledon Pharmaceuticals: A Strong Buy on Clinical Progress and Strategic Positioning
Eledon Pharmaceuticals: A Strong Buy on Robust Financials and Promising Clinical Trials
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Eledon Pharmaceuticals provides Q2 corporate update
Eledon Pharmaceuticals (ELDN) Receives a Buy from Noble Financial